




# Quantum-Si

## Investor Presentation

JOHN STARK, CEO | INVESTOR UPDATE

JUNE 2021



## Forward-Looking Statements

This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results of Quantum-Si Incorporated (the “Company”) may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance, development of products and services, potential regulatory approvals, the size and potential growth of current or future markets for the Company’s future products and services, or the Company’s plans, expectations or future operations, financial position, revenues, costs or expenses. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company’s business; the inability to maintain the listing of the Company’s shares of Class A common stock on The Nasdaq Stock Market; the ability to recognize the anticipated benefits of the Company’s recently-completed business combination, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the Company’s ability to raise financing in the future; the success, cost and timing of the Company’s product development activities; the potential attributes and benefits of the Company’s products and services; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is developing; the size and growth potential of the markets for the Company’s future products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services following anticipated commercial launch; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties indicated from time to time in the proxy statement/prospectus relating to the business combination, including those under “Risk Factors” therein, and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

NCH 0.00 Nasdaq  
\$172.95

Nasdaq Composite

▲ 0.40%  
+49.09 14,069.42

ATLISCO 0.02% +0.01 \$54.78

COMCAST -0.26% -\$6.72

PEPSICO +0.38% +\$14.25

Nasdaq QuantumSi

QSI  
NasdaqListed

UNCH 0.00 \$9.75

DOWJONES

DJI ▲ 0.04%  
+13.36 34,479.60

amazon +0.05% +\$1.67 \$3,348.50

PayPal +0.38% +\$22.48  
PayPal Holdings, Inc.

Nasdaq Composite  
▲ 0.40%  
+\$6.09 14,069.42

S&P 500 INDEX  
SP500 ▲ 0.19%  
+\$8.26 4,247.44

COMCAST -0.26% -\$6.73


cisco Cisco Systems, Inc.  
▲ 0.01% +\$6.73

QuantumSi





What if we could understand  
how disease is progressing in  
real-time and provide  
immediate guidance on  
personalized treatment?



# The Next Transformation Anticipated in Life Sciences: Single Molecule Protein Sequencing

Genomics



qPCR



Sanger



Microarrays

454  
SEQUENCING



illumina®



Analog Gene and Transcript Resolution

Birth of Digital DNA Sequencing

Single Molecule, Benchtop Systems and Clinical

1990s

2000s

2010s - Current

Analog Protein and Peptide Level

Bench Top Single Molecule/Amino Acid Resolution



Mass Spec




ELISA

Without legacy restrictions,  
QSi has the opportunity to compete successfully




# Why is understanding the Proteome transformative?

Proteins represents the clinical end point and building blocks of life



What is there?



How much is there?



How has it been changed?

## Current State of Treatment

90% of Approved Drugs Target a Protein<sup>1</sup>

## Novel Therapies

85% of proteome undrugged<sup>2</sup>

## Patient Care

>100M Immunoassay Test/Year<sup>3</sup>

<sup>1</sup> The Human Proteome Tissue Atlas – Druggable Proteome, 2015, The Human Protein Atlas Project

<sup>2</sup> A Quest to Drug the Undruggable, June, Chemical & Engineering News, Volume 96, Issue 26, 2018

<sup>3</sup> "NPS Focus", Rainbow makers, Royal Society of Chemistry (RSC), 2003, retrieved 29 December 2012

# End-to-End Protein Analysis Platform



Sample Prep

Carbon

Universal sample preparation for both protein and DNA.



Sequencing

Platinum

Single Molecule Analysis



Analysis

Cloud

Secure data storage and analysis workflows.



# Potential Digital Disruption and Expansion of a \$44B Market

## Quantitative Proteomics

\$31B (2020) 3% CAGR



Pharmaceutical and diagnostic development

>20,000

Proteomics instrument installations

## Sequencing

\$5B (2020) 8% CAGR




Basic Research, Discovery and Emerging Clinical Application

>16,000

Bench Top DNA Digital Sequencing Systems

## Clinical Testing

\$8B (2020) 15% CAGR



Precision Medicine Targeted Therapies

>132M

Molecular tests performed each year in U.S

Data collected from SDI Global Report 2020 and Cowen Equity Research Life Science tools Kit 12th Edition.

# Novel Biological Understanding: Next Frontier of Assessing Recurrence and Treatment


## Post-translational Modifications

Our technology detects post-translational modifications like any other amino acid. We can currently recognize phosphorylated tyrosine on chip and are working on other PTMs.


## Pathways Activation

Tyrosine phosphorylation is a marker for pathway activation, e.g. how cells responds to drugs, infection.

Tyrosine



Phosphorylated Tyrosine



Estimated \$10B/Year Therapy Market Opportunity  
EGFR/HER2 (Breast and Lung)

# And finally delivering on what we believe the market demands

	Mass Spec	Digital DNA Sequencing	Single Molecule DNA Sequencing	Quantum-Si
Quantitative Analysis (Protein)	✓	---	---	✓
Quantitative Analysis (DNA)	---	✓	✓	✓
Benchtop System	---	✓	---	✓
Single Molecule	---	---	✓	✓



# Well Positioned to be a Leader in the Proteomics Revolution




Sample Preparation	✓	---	---	✓
Single Molecule	---	---	✓	✓
Analysis Platform*	---	---	✓	✓
Protein Identification	---	✓	✓	✓
Protein Quantitation	---	✓	---	✓
Analysis Output	---	---	✓	✓



# Pathway for Growth and Customer Adoption

## Status:

- Optimized Workflow and Data Analysis
- Scaled Production/Supply Chain
- First Two Systems Shipped Q1, 2021



# Valuation Potential

## Illumina

Revenues  
\$ Millions



- 2006 launch
- Leveraged foothold in the genomics market

## 10X Genomics

Revenues  
\$ Millions



- 2016 launch
- Leveraged the Human Cell Atlas program and Illumina footprint

## Seer

Pre-commercial

\$1.9BN+ Market Cap Today<sup>1</sup>

- 2020 IPO
- 2022 anticipated commercial launch<sup>2</sup>

<sup>1</sup>As of market close on Friday, January 29 2021

<sup>2</sup><https://www.genomeweb.com/proteomics-protein-research/seer-using-310m-fundraise-prep-broad-commercial-launch-proteomic>



# Meet the Team



**JONATHAN  
ROTHBERG**

*Executive  
Chairman*



**JOHN  
STARK**

*Chief Executive  
Officer*



**MIKE  
MCKENNA**

*Chief Operations  
Officer*



**CHRISTIAN  
LAPOINTE**

*General  
Counsel*



**CLAUDIA  
DRAYTON**

*Chief Financial  
Officer*



**MATT  
DYER**

*Chief Business  
Officer*



**GERARD  
SCHMID**

*Head of Chip  
Manufacturing*



**TODD  
REARICK**

*Chief Technology  
Officer*



**KIEREN  
PATEL**

*Head of Product  
and Marketing*



**BRIAN  
REED**

*Head of  
Research*



**FAISAL  
AHMAD**

*Head of  
Optical Devices*



**MEL  
DAVEY**

*Head of  
Software*



**MIKE  
FERRIGNO**

*Head of  
Hardware*




**LINDSAY  
THOMPSON**

*Head of  
People*

>120 Employees



# Pioneering Next Generation Single Molecule Sequencing



- Commercializing single-molecule protein sequencing platform scaled by a first of its kind semiconductor chip with over 550<sup>1</sup> issued and pending patents
- Positioned for massive market expansion and to digitize a \$44B<sup>2</sup> legacy proteomics research and diagnostic markets
- Leveraging decades of advancement in digital DNA sequencing, QSi is poised to become the market leader in single molecule protein sequencing

<sup>1</sup>Over 100 issued patents and 450 pending patent applications across 125 patent families

<sup>2</sup>Data collected from SDI Global Report 2020 and Cowen Equity Research Life Science tools Kit 12th Edition.